Sagimet Biosciences Inc. (SGMT) Reports Positive 52-Week OLE Data for Denifanstat in Acne

Sagimet reported positive 52-week open-label extension results from Ascletis' Phase 3 trial of denifanstat in moderate to severe acne, with ~75—80% lesion reductions from original baseline among completers and generally well-tolerated safety, and expects to begin U.S. AURORA Phase 3 screening in Oc…